Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty ( EMPRISE ) study
- 1 December 2021
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 24 (3) , 442-454
Abstract
Aim: To investigate effectiveness and safety outcomes among patients with type 2 diabetes (T2D) initiating empagliflozin versus dipeptidyl peptidase‐4 (DPP‐4) inhibitor treatment across the broad spectrum of cardiovascular risk. Methods: In a population‐based cohort study we identified 39 072 pairs of 1:1 propensity score‐matched adult patients with T2D initiating empagliflozin or DPP‐4 inhibitors, using data from 2 US commercial insurance databases and Medicare between August 2014 and September 2017. The primary outcomes were a composite of myocardial infarction (MI)/stroke, and hospitalization for heart failure (HHF). Safety outcomes were bone fractures, lower‐limb amputations (LLAs), diabetic ketoacidosis (DKA), and acute kidney injury (AKI). We estimated pooled hazard ratios (HRs) and 95% confidence intervals (CIs) adjusting for more than 140 baseline covariates. Results: Study participants had a mean age of 60 years and only 28% had established cardiovascular disease. Compared to DPP‐4 inhibitors, empagliflozin was associated with similar risk of MI/stroke (HR 0.99 [95% CI 0.81‐1.21]), and lower risk of HHF (HR 0.48 [95% CI 0.35‐0.67] and 0.63 [95% CI 0.54‐0.74], based on a primary and any heart failure discharge diagnosis, respectively). The HR was 0.52 (95% CI 0.38‐0.72) for all‐cause mortality (ACM) and 0.83 (95% CI 0.70‐0.98) for a composite of MI/stroke/ACM. Empagliflozin was associated with a similar risk of LLA and fractures, an increased risk of DKA (HR 1.71 [95% CI 1.08‐2.71]) and a decreased risk of AKI (HR 0.60 [95% CI 0.43‐0.85]). Conclusions: In clinical practice, the initiation of empagliflozin versus a DPP‐4 inhibitor was associated with a lower risk of HHF, ACM and MI/stroke/ACM, a similar risk of MI/stroke, and a safety profile consistent with documented information.Keywords
Funding Information
- National Institute on Aging (K08AG055670)
This publication has 40 references indexed in Scilit:
- The validity of administrative data to identify hip fractures is high—a systematic reviewJournal of Clinical Epidemiology, 2013
- A systematic review of validated methods for identifying heart failure using administrative dataPharmacoepidemiology and Drug Safety, 2012
- Positive predictive value of automated database records for diabetic ketoacidosis (DKA) in children and youth exposed to antipsychotic drugs or control medications: a tennessee medicaid studyBMC Medical Research Methodology, 2011
- A combined comorbidity score predicted mortality in elderly patients better than existing scoresJournal of Clinical Epidemiology, 2011
- Validation of claims‐based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially‐insured populationPharmacoepidemiology and Drug Safety, 2010
- Validity of International Classification of Diseases, Ninth Revision, Clinical Modification Codes for Acute Renal FailureJournal of the American Society of Nephrology, 2006
- Accuracy of medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital recordsAmerican Heart Journal, 2004
- Validating Administrative Data in Stroke ResearchStroke, 2002
- The Use of Automated Data to Identify Complications and Comorbidities of DiabetesJournal of Clinical Epidemiology, 1999
- Identification of fractures from computerized medicare filesJournal of Clinical Epidemiology, 1992